The Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001, can be a fruitless and thorny ground for plaintiffs, and many seek to avoid it entirely by bringing their insurance claims under state law. The Supreme Court has increasingly circumscribed such state-law claims, however, finding the pre-emptive sweep of ERISA to be so “extraordinary” that it bars all claims of close relation. Metropolitan Life Ins. Co. v. Taylor,
The Linds fall in a long — and growing— line of plaintiffs who find themselves squeezed between the broad preemptive sweep of ERISA and narrow construction of remedies under the Act itself. We find that the Linds have viable claims neither inside ERISA nor outside it, and we AFFIRM the district court’s grant of summary judgement and denial of leave to amend the claim.
I. Facts and Procedural Background
James D. Lind, a construction manager, was covered by Aetna under his wife’s health insurance plan. In July 2002, he was diagnosed with Multiple Sclerosis (“MS”). His symptoms, including recurrent and severe headaches, dizziness, and depression, left him unable to work. Shortly after the diagnosis, Aetna referred Mr. Lind to Dr. Jorge Gonzalez, a neurologist, for treatment. Dr. Gonzalez prescribed a three-drug regime — Copaxone, Provigil, and Klonopin — which successfully reversed Mr. Lind’s symptoms, allowing him to return to work.
In February 2003, Mr. Lind went to a pharmacy to pick up his Provigil renewal, only to be told by the pharmacist that no further renewals had been authorized. Mr. Lind informed Dr. Gonzalez of the denial, who in turn informed Aetna of his vigorous objections to the change. Aetna told Dr. Gonzalez that Mr. Lind must first try Ritalin, a “step drug,” before the company would authorize payment for further Provigil prescriptions. Dr. Gonzalez, after protesting, wrote Mr. Lind a prescription for Ritalin. Mr. Lind filled the prescription, began taking the drug, and almost immediately experienced a renewal of his symptoms. Aetna re-authorized payment for Provigil several days later, but the new symptoms proved irreversible, and Mr. Lind remains disabled and unable to work.
On May 21, 2004, the Linds filed a petition in the District Court of Tulsa County, Oklahoma, against Aetna, alleging medical
II. Preemption of state-law claims
We begin by addressing whether the Linds’ state-law claims are barred by ERISA, which preempts all state laws that “relate to” employee benefit plans. 29 U.S.C. § 1144(a). It is undisputed that the Linds’ original claims are based on state law and that Aetna’s plan is an employee benefit plan; the issue is whether the claims “relate to” the Aetna plan. This court reviews the district court’s determination of preemption de novo. Airparts Co. v. Custom Benefit Servs. of Austin, Inc.,
Both the language of the statute and its legislative history indicate that Congress intended ERISA to sweep with broad force. The Act’s stated purpose is to protect the participants in employee benefit plans by “providing for appropriate remedies, sanctions, and ready access to the Federal courts.” 29 U.S.C. § 1001(b). The conference report shows that such language was intended to parallel that of the Labor-Management Relations Act of 1947, which “pre-empts any ‘state-law claim [whose resolution] is substantially dependent upon the analysis of the terms of an agreement made between the parties in a labor contract.’ ” Pilot Life Ins. Co. v. Dedeaux,
Appellants face an unenviable task in distinguishing their case from Davila, in which the Supreme Court found preemption on similar claims and nearly identical facts. Juan Davila’s treating physician prescribed Vioxx to remedy Mr. Davila’s arthritis, but Aetna refused to authorize payment until Mr. Davila tried a “step drug,” Naprosyn, first. Davila,
Appellants also argue that their claims for medical negligence and respondeat superior are outside the scope of Davila. They claim that a Dr. Jane Doe, employed by Aetna, “made the determination that Ritalin rather than Provigil was the appropriate drug to treat Lind’s MS. Aetna then imposed this determination upon Lind’s treating physician.” Appellants’ Br. 10. In support of this claim, the Linds cite Pacificare of Oklahoma, Inc. v. Burrage,
III. ERISA claims
We now turn to whether the Linds were properly denied leave to amend their complaint to include ERISA claims. We have held that, under Fed.R.Civ.P. 15(a), “leave to amend shall be given freely,” although “the district court may deny leave to amend where amendment would be futile. A proposed amendment is futile if the complaint, as amended, would be subject to dismissal.” Bradley v. J.E. Val-Mejias,
Justice Ginsburg and others have noted the lopsided results this interpretation produces: “Because the Court has coupled an encompassing interpretation of ERISA’s preemptive force with a cramped construction of the equitable relief allowable under § 502(a)(3), a regulatory vacuum exists: [Vlirtually all state law remedies are preempted but very few federal substitutes are provided.” Davila,
Notwithstanding this suggestion, our interpretation of § 502(a) has continued to follow the narrow path laid out by Great-West. In Millsap v. McDonnell Douglas Corp.,
The claims here mirror those in Great-West, Millsap, and Cattery. The Linds are seeking compensatory damages for restitution of lost wages, exacerbation of Mr. Lind’s medical condition, and pain and suffering, as well as punitive damages. These claims do not seek “to restore to the plaintiff particular funds or property in the defendant’s possession,” but rather “to impose personal liability.” Great-West,
This is not to say that the Linds, or similarly situated individuals, are entirely without remedy. Had the Linds paid for the Provigil out of pocket, they could have then sued for reimbursement or a reinstatement of coverage. Cattery suggests that, under some circumstances, policyholders might also have an actionable
IV. Conclusion
The Linds’ original claims are entirely preempted by ERISA, and we AFFIRM their dismissal by the district court. Because appellants offered no new, non-frivolous claims, we AFFIRM the district court’s denial of leave to amend the complaint.
Notes
Appellants also raise claims stemming from a second alleged incident of misconduct by Aetna, two months later. Because those claims were never before the lower court, we decline to examine them here. In re Walker,
